Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
- 27 July 2000
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 343 (4), 246-253
- https://doi.org/10.1056/nejm200007273430403
Abstract
Background Intravenous infusion of nesiritide, a brain (B-type) natriuretic peptide, has beneficial hemodynamic effects in patients with decompensated congestive heart failure. We investigated the clinical use of nesiritide in such patients. Methods Patients hospitalized because of symptomatic congestive heart failure were enrolled in either an efficacy trial or a comparative trial. In the efficacy trial, which required the placement of a Swan–Ganz catheter, 127 patients with a pulmonary-capillary wedge pressure of 18 mm Hg or higher and a cardiac index of 2.7 liters per minute per square meter of body-surface area or less were randomly assigned to double-blind treatment with placebo or nesiritide (infused at a rate of 0.015 or 0.030 μg per kilogram of body weight per minute) for six hours. In the comparative trial, which did not require hemodynamic monitoring, 305 patients were randomly assigned to open-label therapy with standard agents or nesiritide for up to seven days. Results In the efficacy trial, at six hours, nesiritide infusion at rates of 0.015 and 0.030 μg per kilogram per minute decreased pulmonary-capillary wedge pressure by 6.0 and 9.6 mm Hg, respectively (as compared with an increase of 2.0 mm Hg with placebo, P<0.001), resulted in improvements in global clinical status in 60 percent and 67 percent of the patients (as compared with 14 percent of those receiving placebo, P<0.001), reduced dyspnea in 57 percent and 53 percent of the patients (as compared with 12 percent of those receiving placebo, P<0.001), and reduced fatigue in 32 percent and 38 percent of the patients (as compared with 5 percent of those receiving placebo, P<0.001). In the comparative trial, the improvements in global clinical status, dyspnea, and fatigue were sustained with nesiritide therapy for up to seven days and were similar to those observed with standard intravenous therapy for heart failure. The most common side effect was dose-related hypotension, which was usually asymptomatic. Conclusions In patients hospitalized with decompensated congestive heart failure, nesiritide improves hemodynamic function and clinical status. Intravenous nesiritide is useful for the short-term treatment of decompensated congestive heart failure.Keywords
This publication has 9 references indexed in Scilit:
- Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trialJournal of the American College of Cardiology, 1999
- Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failureJournal of Cardiac Failure, 1998
- Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart FailureCirculation, 1996
- Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart FailureCirculation, 1996
- Electrophysiologic and proarrhythmic effects of intravenous inotropic agentsProgress in Cardiovascular Diseases, 1995
- Natriuretic peptide system in human heart failure.Circulation, 1993
- Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal manJournal of Clinical Endocrinology & Metabolism, 1993
- Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart FailureThe New England Journal of Medicine, 1987
- Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinoneAmerican Heart Journal, 1986